Literature DB >> 9796057

Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines.

J E Eyles1, I D Spiers, E D Williamson, H O Alpar.   

Abstract

Intra-tracheal, intra-nasal and intra-muscular immunisation with admixed Y. pestis sub-units (3 micrograms V, 0.47 microgram F1) or equivalent doses of poly-L-lactide microsphere co-encapsulated antigens was done. Systemic and mucosal responses to F1 and V differed according to immunisation route, and encapsulated status of the sub-units. Irrespective of immunisation site, particulated sub-units stimulated statistically superior primary systemic reactions, with intra-tracheal and nasal microsphere immunisations eliciting superior serum anti-V IgG titres in comparison to intra-muscular injection of free vaccines (p < 0.001 beyond day 8). Pulmonary and nasal delivery of microspheres induced primary serum anti-V IgG titres which were greater (p < 0.039) or equal to (p > 0.056) those after intra-muscular injection of spheres. In terms of serum anti-F1 titres, mice responded best to intra-muscular, and comparatively poorly to intra-nasal immunisations. Intra-tracheal administration of microspheres induced strongest responses in the respiratory tract, dominated by the IgG rather than IgA isotype. An intra-nasal booster immunisation on day 63 potentiated strong local and circulating anti-V IgG titres in microsphere vaccinees. Priming and boosting with free vaccines induced significantly depressed secondary serum anti-F1 titres relative to microsphere immunisations (p < 0.024 at days 78 and 120). In contrast to other priming sites, intra-tracheal instillation of encapsulated vaccines facilitated the induction of IgG antibody to both F1 and V in day 146 broncho-alveolal washings. With the exception of primary responses to F1 in mice immunised intra-tracheally with microspheres, IgG1 was the dominant subclass of anti-F1/V IgG in serum. We conclude that introduction of biodegradable microspheres containing the F1 and V sub-units into to the upper or lower respiratory tract engenders immune responses of a magnitude comparable with that induced by parenteral immunisation, and may present a means of protecting individuals from plague.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796057     DOI: 10.1016/s0264-410x(98)00089-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis.

Authors:  Anna N Honko; Nammalwar Sriranganathan; Cynthia J Lees; Steven B Mizel
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

2.  Chimeric flagellin expressed by Salmonella typhimurium induces an ESAT-6-specific Th1-type immune response and CTL effects following intranasal immunization.

Authors:  Hui Zhang; Liu Liu; Ke Wen; Jinlin Huang; Shizhong Geng; Junsong Shen; Zhiming Pan; Xinan Jiao
Journal:  Cell Mol Immunol       Date:  2011-08-15       Impact factor: 11.530

3.  Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.

Authors:  Brian R Sloat; Zhengrong Cui
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

4.  Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.

Authors:  Helen C Flick-Smith; Jim E Eyles; Richard Hebdon; Emma L Waters; Richard J Beedham; Tony J Stagg; Julie Miller; H Oya Alpar; Les W J Baillie; E Diane Williamson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

5.  Repertoire of HLA-DR1-restricted CD4 T-cell responses to capsular Caf1 antigen of Yersinia pestis in human leukocyte antigen transgenic mice.

Authors:  Julie A Musson; Rebecca Ingram; Guillaume Durand; Stephanie Ascough; Emma L Waters; M Gillian Hartley; Timothy Robson; Bernard Maillere; E Diane Williamson; Shiranee Sriskandan; Daniel Altmann; John H Robinson
Journal:  Infect Immun       Date:  2010-07-26       Impact factor: 3.441

6.  Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts.

Authors:  Philip A Arlen; Michael Singleton; Jeffrey J Adamovicz; Yi Ding; Abdolreza Davoodi-Semiromi; Henry Daniell
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

Review 7.  Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Authors:  Yuchen Fan; James J Moon
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01

8.  Intranasal immunization with recombinant Toxoplasma gondii actin depolymerizing factor confers protective efficacy against toxoplasmosis in mice.

Authors:  Zhuanzhuan Liu; Litian Yin; Yaqing Li; Fei Yuan; Xiaofan Zhang; Jiazhi Ma; Hongmei Liu; Yanjuan Wang; Kuiyang Zheng; Jianping Cao
Journal:  BMC Immunol       Date:  2016-10-06       Impact factor: 3.615

9.  Mucosal immunoglobulins protect the olfactory organ of teleost fish against parasitic infection.

Authors:  Yong-Yao Yu; Weiguang Kong; Ya-Xing Yin; Fen Dong; Zhen-Yu Huang; Guang-Mei Yin; Shuai Dong; Irene Salinas; Yong-An Zhang; Zhen Xu
Journal:  PLoS Pathog       Date:  2018-11-05       Impact factor: 6.823

10.  Local and systemic immune responses to intratracheal instillation of antigen and DNA vaccines in mice.

Authors:  Catherine Lombry; Aline Marteleur; Mohammed Arras; Dominique Lison; Jamila Louahed; Jean-Christophe Renauld; Véronique Préat; Rita Vanbever
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.